Esketamine linked to remission across six TRD clinical trials

For many patients with major depressive disorder, reaching remission — not just partial response — can significantly alter the course of illness, lowering the risk of relapse and improving day‐to‐day functioning. Yet that goal remains elusive for those with treatment‐resistant depression (TRD), where repeated medication failures, comorbid conditions, and lingering symptoms complicate care. Data from the STAR*D trial highlights the challenge that by the third line of treatment, fewer than one in six patients achieved remission.